Shenzhen Kangtai Biological Products Co., Ltd.

Company Profile

1、Well-Structured R&D Pipeline Focused on Multivalent Combination Vaccines, Adult Vaccines, and Innovative Vaccines The company has always regarded technological innovation as the cornerstone of its development, continuously increasing R&D investment and adhering to a strategy that prioritizes independent research while complementing it with collaborative development. This approach ensures the effective transformation of R&D achievements. The company holds over 80 patents and has nearly 30 pipeline products under development. With a robust and diversified product pipeline that demonstrates strong industry competitiveness, the R&D efforts are primarily focused on multivalent and combination vaccines, adult vaccines, and innovative vaccines. The company has a leading position in polyvalent vaccines. The first is the acellular diphtheria-tetanus-based combined Haemophilus influenzae type b vaccine (tetravalent vaccine) , which is the largest number of domestic vaccines The combined vaccine of adsorbed acellular diphtheria-pertussis-inactivated poliomyelitis and Haemophilus influenzae type b (pentavalent vaccine) is in Phase I clinical trials, and also has the research and development foundation of hexavalent vaccine The second is the combined vaccine based on leprosy. The second vaccine has been put on the market. The third MMR vaccine is in phase I clinical trials Third, the establishment of a joint venture with astrazeneca to carry out respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) vaccine combination research and development. In terms of multivalent vaccines, the company's self-developed “Dual-carrier 13-valent pneumococcal polysaccharide conjugate vaccine” is the world's first, the 20-valent pneumococcal polysaccharide conjugate vaccine is in phase I and Phase II clinical trials, and the development of 24-valent pneumococcal polysaccharide conjugate vaccine is advancing. The company's product pipeline has achieved a full life cycle layout, especially targeting the growth potential of adult immunization needs. In addition to hepatitis B vaccine (20μg, 60μg), 23-valent pneumococcal polysaccharide vaccine, freeze-dried human rabies vaccine (human diploid cells), and live attenuated varicella vaccine (all people aged 13 years and above), etc. the company's adult vaccine also layout of the tetravalent influenza virus split vaccine, tetanus vaccine, 24-valent pneumococcal polysaccharide conjugate vaccine, herpes zoster vaccine, respiratory syncytial virus vaccine (RSV) and other vaccines. The company pays attention to the application research of new vaccine technology path and the establishment of new technology platform, including mRNA technology, viral vector technology, new adjuvant technology, etc., the company also continues to strengthen external cooperation and actively explore the future development direction of the industry. 2、Established Brand Value and Strong Commercialization Capabilities Built Over Years As an enterprise deeply engaged in the field of human vaccines for more than 30 years, since its inception, the company has always focused on human vaccine research and development, production and sales, with strong R&D strength, rich product structure and layout, innovative technology platform, strict quality management system, safe and stable product quality, etc. , has created a solid market position and good brand advantage, has developed into a domestic human vaccine field leading enterprises. The company has accumulated a wealth of sales experience, channel resources, the company's own sales team and closed promotion business team total of more than 1000 people, has achieved the National 31 provinces, autonomous regions, municipalities covering the whole. In the future, with its rich product pipeline, innovative research and development capabilities, especially the continuous listing of blockbuster products, the company will further enhance its brand value and consolidate its leading position in the domestic vaccine industry. 3、With International Experience and Foundations, the Company Adheres to the "Inbound" and "Outbound" Strategy. Since its establishment, the company has undertaken the technology transfer of international vaccine giants such as Merck of the United States, Sanofi Pasteur of France, Intravacc of the Netherlands and astrazeneca of the United Kingdom, not only enrich their own technology layout and reserves, but also enhance the ability of independent innovation, and promote the transformation of independent innovation technology. While “Bringing in”, the company actively promotes the development strategy of “Going out”, and has signed cooperation agreements with more than 10 national partners to build an international export system from products to technology, at present, the company's international cooperation network layout has covered Southeast Asia, South Asia, the Middle East, Central Asia, North Africa, Eastern Europe, Latin and other regions, it has carried out various forms of overseas cooperation such as export of finished products and technology transfer. In the future, the company will continue to increase its international expansion efforts, actively explore international market cooperation, strengthen overseas product registration, and develop diversified sales channels for its products, we are committed to becoming a well-known biological vaccine supplier in the world. 4、 Build a high-standard quality management system and a strong moat for high-quality products The company has always regarded “Quality as life” as its core business philosophy, and is committed to building a quality management system in line with international standards, the quality management system covers the whole life cycle of products from research and development, production, storage, circulation to after-sales service, ensuring that products meet the intended use and standards at each key point. The company introduced advanced information systems, such as laboratory information management systems (LIMS) and manufacturing execution systems (MES) , to build a “Full life cycle” information management of vaccine production, the whole process of drug production, quality control and product release, storage and transportation can be traced to improve the scientificity and accuracy of quality control. In addition, the company actively introduces and absorbs international cutting-edge Technologies and advanced quality management concepts, benchmarking international standards, and continuously improving the company's total quality management and control capabilities to achieve continuous upgrading of product quality. 5、Emphasize Talent Development, Build a Stable Talent Reserve Team The company attaches great importance to the introduction and training of talents, pay attention to diversified, inter-disciplinary talent team building. Internally, the company has established a complete training system with the online learning platform of Kangtai University as the carrier, and tailored the learning path map for employees of different ranks, to help employees achieve comprehensive improvement from professional skills to comprehensive quality. Externally, the company has actively established deep cooperation with well-known universities and jointly opened vaccine characteristic classes to provide employees with a broader space for learning and development. At the same time, the company also through the optimization of the salary system, improve the long-term incentive mechanism, improve the cohesion and competitiveness of employees. After years of operation and development, the company has built a stable and experienced management and R&D team, and effectively promote the company's efficient operation, R&D Innovation and product quality improvement, promote the long-term sustainable development of the company.